Chemomab
2 known investors
Chemomab Therapeutics is a clinical-stage biotechnology company developing therapeutics for fibro-inflammatory diseases. Its lead candidate, nebokitug (CM-101), is a monoclonal antibody that neutralizes the CCL24 protein to interrupt the inflammation-and-fibrosis cycle in conditions such as primary sclerosing cholangitis and liver, skin, and lung fibrosis.
Biotech
Investors · 2
In the news
Frequently asked questions
- What does Chemomab do?
- Chemomab Therapeutics is a clinical-stage biotechnology company developing therapeutics for fibro-inflammatory diseases. Its lead candidate, nebokitug (CM-101), is a monoclonal antibody that neutralizes the CCL24 protein to interrupt the inflammation-and-fibrosis cycle in conditions such as primary sclerosing cholangitis and liver, skin, and lung fibrosis.
- Who are Chemomab's investors?
- Chemomab's investors include Altium Capital, OrbiMed.